PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520138-31-00

Enrollment

Registered

2026-02-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early-stage favorable classic Hodgkin lymphoma

Brief summary

Progression-free survival (PFS) at 1 year

Detailed description

Remission status after pembrolizumab therapy and after consolidation Radiotherapy, Progression-free survival (PFS) at 2 years, Overall survival (OS) at 1 year and at 2 years, Adverse events during and after anti-PD-1 therapy, Patient-reported outcomes at baseline, during treatment and during follow-up, Rate of early discontinuation of trial treatment, Rate and types of HL-directed treatment administered in addition to trial treatment, Event-free survival (EFS) at 1 year and at 2 years

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS) at 1 year	—

Secondary

Measure	Time frame
Remission status after pembrolizumab therapy and after consolidation Radiotherapy, Progression-free survival (PFS) at 2 years, Overall survival (OS) at 1 year and at 2 years, Adverse events during and after anti-PD-1 therapy, Patient-reported outcomes at baseline, during treatment and during follow-up, Rate of early discontinuation of trial treatment, Rate and types of HL-directed treatment administered in addition to trial treatment, Event-free survival (EFS) at 1 year and at 2 years	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 11, 2026